Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Pieris Pharmaceuticals Inc
(NQ:
PIRS
)
11.08
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Pieris Pharmaceuticals Inc
< Previous
1
2
Next >
Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split
April 19, 2024
Via
ACCESSWIRE
Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential
March 27, 2024
Via
ACCESSWIRE
Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
August 17, 2023
Via
ACCESSWIRE
Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring
July 18, 2023
Via
ACCESSWIRE
Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates
May 10, 2023
Via
ACCESSWIRE
Pieris Pharmaceuticals Reports Full-Year 2022 Financial Results and Business Updates
March 29, 2023
Via
ACCESSWIRE
Pieris Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 02, 2022
Via
ACCESSWIRE
Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 04, 2022
Via
ACCESSWIRE
Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study
June 21, 2023
Via
ACCESSWIRE
Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference
June 02, 2023
Via
ACCESSWIRE
Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference
May 22, 2023
Via
ACCESSWIRE
Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference
May 21, 2023
Via
ACCESSWIRE
Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402)
May 04, 2023
Via
ACCESSWIRE
Pieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023
May 02, 2023
Via
ACCESSWIRE
Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa (PRS-343) At 2023 AACR Annual Meeting
April 17, 2023
Via
ACCESSWIRE
Pieris Pharmaceuticals to Host Year End 2022 Investor Call and Provide Corporate Update on March 29, 2023
March 24, 2023
Via
ACCESSWIRE
Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346)
January 10, 2023
Via
ACCESSWIRE
Pieris Pharmaceuticals To Present at Evercore ISI Healthconx Conference
November 23, 2022
Via
ACCESSWIRE
Pieris Pharmaceuticals to Present at Jefferies London Healthcare Conference
November 09, 2022
Via
ACCESSWIRE
Pieris Pharmaceuticals Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220
November 01, 2022
Via
ACCESSWIRE
Pieris Pharmaceuticals To Host Third Quarter 2022 Investor Call and Provide Corporate Update on November 2, 2022
October 26, 2022
Via
ACCESSWIRE
Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 08, 2022
Via
ACCESSWIRE
Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS
August 24, 2022
Via
ACCESSWIRE
Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022
July 28, 2022
BOSTON, MA / ACCESSWIRE / July 28, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®...
From
Pieris Pharmaceuticals, Inc.
Via
AccessWire
Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022
July 28, 2022
Via
ACCESSWIRE
Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference
June 02, 2022
BOSTON, MA / ACCESSWIRE / June 2, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology...
From
Pieris Pharmaceuticals, Inc.
Via
AccessWire
Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference
May 18, 2022
BOSTON, MA / ACCESSWIRE / May 18, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology...
From
Pieris Pharmaceuticals, Inc.
Via
AccessWire
Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 11, 2022
Company To Host an Investor Conference Call On Wednesday, May 11, 2022 At 8:00 Am EDT BOSTON, MA / ACCESSWIRE / May 11, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage...
From
Pieris Pharmaceuticals, Inc.
Via
AccessWire
Pieris Pharmaceuticals To Host First Quarter 2022 Investor Call and Provide Corporate Update on May 11, 2022
May 04, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
From
Pieris Pharmaceuticals, Inc.
Via
AccessWire
Pieris Pharmaceuticals Reports Full-Year 2021 Financial Results and Provides Corporate Update
March 01, 2022
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON TUESDAY, MARCH 1, 2022 AT 8:00 AM EST - Initiated efficacy part of phase 2a study of PRS-060/AZD1402; expected topline readout this year - Dosed first...
From
Pieris Pharmaceuticals, Inc.
Via
AccessWire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.